PDF下载 ( 1596 KB)
Advances in research and development of new drugs for antiviral therapy for chronic hepatitis B
-
摘要:
慢性HBV感染是全球主要的疾病负担之一。目前乙型肝炎的抗病毒治疗主要包括IFN与核苷和核苷酸类药物。以这两类药物为基础所制订的现有治疗方案均不能显著提高功能性治愈的比例。随着对HBV复制周期以及病毒与宿主细胞特异性相互作用了解的不断深入,针对上述过程中不同的作用靶点,对抗HBV新药的研发进展进行了总结和评述。
Abstract:Chronic hepatitis B virus( HBV) infection is one of the major disease burdens worldwide. At present,the antiviral therapy for hepatitis B includes interferons and nucleos( t) ide analogues. Current therapeutic regimens based on these drugs cannot significantly increase the proportion of patients with functional cure. With a better understanding of HBV replication cycle and specific virus- host cell interactions,this article summarizes and reviews the advances in the research and development of new drugs for HBV with a focus on different action targets during the above processes.
-
Key words:
- hepatitis B,chronic /
- antiviral agents /
- therapy
-
[1]DANDRI M,PETERSEN J.Latest developments in the treatment of hepatitis B[J].Minerva Gastroenterol Dietol,2016,62(1):88-102. [2]NI Y,LEMPP FA,MEHRLE S,et al.Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes[J].Gastroenterology,2014,146(4):1070-1083. [3]YAN H,ZHONG G,XU G,et al.Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus[J].ELife,2012,1:e00049. [4]PETERSEN J,DANDRI M,MIER W,et al.Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein[J].Nat Biotechnol,2008,26(3):335-341. [5]VOLZ T,ALLWEISS L,BEN MBAREK M,et al.The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus[J].J Hepatol,2013,58(5):861-867. [6]BOGOMOLOV P,VORONKOVA N,ALLWEISS L,et al.A proof-of-concept Phase 2a clinical trial with HBV/HDV entry inhibitor Myrcludex B[J].Hepatology,2014,60:1279a-1280a. [7]KONIGER C,WINGERT I,MARSMANN M,et al.Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses[J].Proc Natl Acad Sci U S A,2014,111(40):e4244-e4253. [8]CUI X,McA LLISTER R,BOREGOWDA R,et al.Does tyrosyl DNA phosphodiesterase-2 play a role in hepatitis B virus genome repair?[J].PLoS One,2015,10(6):e0128401. [9]KENNEDY EM,BASSIT LC,MUELLER H,et al.Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease[J].Virology,2015,476(2):196-205.10]RAMANAN V,SHLOMAI A,COX DB,et al.CRISPR/Cas9cleavage of viral DNA efficiently suppresses hepatitis B virus[J].Sci Rep,2015,5(6):10833.11]ZHEN S,HUA L,LIU YH,et al.Harnessing the clustered regularly interspaced short palindromic repeat(CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus[J].Gene Ther,2015,22(5):404-412. [12]CAI D,MILLS C,YU W,et al.Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation[J].Antimicrob Agents Chemother,2012,56(8):4277-4288. [13] GUO H,JIANG D,ZHOU T,et al.Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus:an intermediate of covalently closed circular DNA formation[J].J Virol,2007,81(22):12472-12484. [14]LUCIFORA J,XIA Y,REISIGNER F,et al.Specific and nonhepatotoxic degradation of nuclear hepatitis B virus ccc DNA[J].Science,2014,343(6176):1221-1228. [15]ZLOTNICK A,VENKATAKRISHNAN B,TAN Z,et al.Core protein:a pleiotropic keystone in the HBV lifecycle[J].Antiviral Res,2015,121(9):82-93. [16]BELLOIN L,PALUMBO GA,LUPACCHINI L,et al.Capsid drugs HAP12 and AT130 target HBV core protein nuclear functions[J].J Hepatol,2015,62(Suppl 2):s513-s514. [17]DERES K,SCHRDER CH,PAESSENS A,et al.Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids[J].Science,2003,299(5608):893-896. [18]STRAY SJ,BOURNE CR,PUNNA S,et al.A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly[J].Proc Natl Acad Sci U S A,2005,102(23):8138-8143. [19]KLUMPP K,SHIMADA T,ALLWEISS L,et al.High antiviral activity of the HBV core inhibitor NVR 3-778 in the humanized UPA/SCID mouse model[J].J Hepatol,2015,62(Suppl 2):s250. [20]LAM A,ESPIRITU C,FLORES O,et al.Effect of the combination of the HBV core inhibitor NVR 3-778 with nucleoside analogs or other HBV core inhibitors on the inhibition of HBV DNA replication in HepG 2.2.15 cells[J].J Hepatol,2015,62(Suppl 2):s559. [21]GANE EJ,SCHWABE C,WALKER K,et al.Phase 1a safety and pharmacokinetics of NVR 3-778,a potential first-in-class HBV core inhibitor[J].Hepatology,2014,60(6):1279a. [22]KLUMPP K,LAM AM,LUKACS C,et al.High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein[J].Proc Natl Acad Sci U S A,2015,112(49):15196-15201. [23]BLOCK TM,LU X,PLATT FM,et al.Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin[J].Proc Natl Acad Sci U S A,1994,91(6):2235-2239. [24]DURANTEL D,ALOTTE C,ZOULIM F.Glucosidase inhibitors as antiviral agents for hepatitis B and C[J].Curr Opin Investig Drugs,2007,8(2):125-129. [25]YU W,GODDARD C,CLEARFIELD E,et al.Design,synthesis,and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen(HBsA g)secretion[J].J Med Chem,2011,54(16):5660-5670. [26]XU YB,YANG L,WANG GF,et al.Benzimidazole derivative,BM601,a novel inhibitor of hepatitis B virus and HBs Ag secretion[J].Antiviral Res,2014,107(7):6-15. [27]NORDEEN F,GROSSE A,JUTEAU JM,et al.Therapeutic efficacy of the amphipathic DNA polymer REP 9AC in the treatment of duck hepatitis B virus infection in vivo[J].Antiviral Res,2009,82(2):a30-a31. [28]MAHTAB M,BAZINET M,VAILLANT A,et al.Establishment of a potent anti-HBsA g response and durable immunological control of viremia with short term immunotherapy after REP 9ACinduced HBsA g seroclearance in chronic HBV infection[J].J Hepatol,2013,58(Suppl 1):s316. [29]Mc CAFFREY AP,NAKAI H,PANDEY K,et al.Inhibition of hepatitis B virus in mice by RNA interference[J].Nat Biotechnol,2003,21(6):639-644. [30]SHLOMAI A,SHAUL Y.Inhibition of hepatitis B virus expression and replication by RNA interference[J].Hepatology,2003,37(4):764-770. [31]SHLOMAI A,SHAUL Y.RNA interference-smal RNAs effectively fight viral hepatitis[J].Liver Int,2004,24(6):526-531. [32]YUEN MF,CHAN HL,GIVEN B,et al.Phase II,dose ranging study of ARC-520,a siRNA-based therapeutic,in patients with chronic hepatitis B virus infection[J].Hepatology,2014,60(6):1280a. [33]SEBESTYN MG,WONG SC,TRUBESKOY V,et al.Targeted in vivo delivery of siRNA and an endosome-releasing agent to hepatocytes[J].Methods Mol Biol,2015,1218:163-186. [34]MACLACHLAN I.Update on the preclinical development of an LNP-based HBV therapeutic[C].10th Annual Meeting of the Oligonucleotide Therapeutics Society.San Diego,California,USA,2014. [35]PHILLIPS S,CHOKSHI S,CHATTERJI U,et al.Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production[J].Gastroenterology,2015,148(2):403-414. [36]NILLON J,MOSS S,COATES N,et al.NVP018,a cyclophilin inhibitor for treatment of chronic HBV infection[J].J Hepatol,2014,60(Suppl 1):s423. [37]JIANG M,BROERING R,TRIPPLER M,et al.Toll-like receptor-mediated immune responses are attenuated in the presence of high levels of hepatitis B virus surface antigen[J].J Viral Hepat,2014,21(12):860-872. [38]ZHANG X,MA Z,LIU H,et al.Role of Toll-like receptor 2in the immune response against hepadnaviral infection[J].J Hepatol,2012,57(3):522-528. [39]WU J,MENG Z,JIANG M,et al.Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells[J].Hepatology,2009,49(4):1132-1140. [40]WU J,LU M,MENG Z,et al.Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice[J].Hepatology,2007,46(6):1769-1778. [41]THOMPSON AJ,COLLEDGE D,RODGERS S,et al.Stimulation of the interleukin-1 receptor and Toll-like receptor 2inhibits hepatitis B virus replication in hepatoma cell lines in vitro[J].Antivir Ther,2009,14(6):797-808. [42]GILES M,VISVANATHAN K,LEWIN S,et al.Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B[J].Gut,2015,64(11):1810-1815. [43]VISVANATHAN K,SKINNER NA,THOMPSON AJ,et al.Regulation of Toll-like receptor-2 expression in chronic hepatitis By the precore protein[J].Hepatology,2007,45(1):102-110. [44]LANFORD RE,GUERRA B,CHAVEZ D,et al.GS-9620,an oral agonist of Toll-like receptor-7,induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees[J].Gastroenterology,2013,144(7):1508-1517. [45]GANE EJ,LIM YS,GORDON SC,et al.The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection[J].J Hepatol,2015,63(2):320-328. [46]REBBAPRAGADA I,BIRKUS G,PERRY J,et al.Molecular determinants of GS-9620-dependent TLR7 activation[J].PLoS One,2016,11(1):e0146835. [47] LANFORD RE,GUERRA B,CHAVEZ D,et al.GS-9620,an oral agonist of Toll-like receptor-7,induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees[J].Gastroenterology,2013,144(7):1508-1517. [48]MENNE S,TUMAS DB,LIU KH,et al.Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620in the Woodchuck model of chronic hepatitis B[J].J Hepatol,2015,62(6):1237-1245. [49]SATO S,LI K,KAMEYAMA T,et al.The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus[J].Immunity,2015,42(1):123-132. [50]KOROLOWICZ K,CZERWINSKI S,IYER R,et al.Antiviral efficacy and induction of host immune responses with SB9200,an oral prodrug of the dinucleotide SB 9000,in the woodchuck model of chronic hepatitis B virus(HBV)infection[J].J Hepatol,2015,62(Suppl 2):s557. [51]CHEN L,FLIES DB.Molecular mechanisms of T cell costimulation and co-inhibition[J].Nat Rev Immunol,2013,13(4):227-242. [52]RAZIORROUH B,SCHRAUT W,GERLACH T,et al.The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+Tcell function[J].Hepatology,2010,52(6):1934-1947. [53] BLACKBURN SD,SHIN H,HAINING WN,et al.Coregulation of CD8+T cell exhaustion by multiple inhibitory receptors during chronic viral infection[J].Nat Immunol,2009,10(1):29-37. [54]FISICARO P,VALDATTA C,MASSARI M,et al.Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B[J].Gastroenterology,2010,138(2):682-693. [55]NEBBIA G,PEPPA D,SCHURICH A,et al.Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection[J].PLoS One,2012,7(10):e47648. [56]SCHRICH A,KHANNA P,LOPES AR,et al.Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection[J].Hepatology,2011,53(5):1494-1503. [57]PEPPA D,MICCO L,JAVAID A,et al.Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection[J].PLoS Pathog,2010,6(12):e1001227. [58]SANGRO B,CROCENZI TS,WELLINGE TH,et al.Phase I dose escalation study of nivolumab(Anti-PD-1;BMS-936558;ONO-4538)in patients(pts)with advanced hepatocellular carcinoma(HCC)with or without chronic viral hepatitis[J].J Clin Oncol,2013,31(Suppl):abstr TPS3111. [59]CHEN L.Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity[J].Nat Rev Immunol,2004,4(5):336-347. [60]EBERT G,ALLISON C,PRESTON S,et al.Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis[J].Proc Natl Acad Sci U S A,2015,112(18):5803-5808. [61]HO GY,BURK RD,KLEIN S,et al.Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia[J].J Natl Cancer Inst,1995,87(18):1365-1371. [62]MOSKOPHIDIS D,LECHNER F,HENGARTNER H,et al.MHC class I and non-MHC-linked capacity for generating an anti-viral CTL response determines susceptibility to CTL exhaustion and establishment of virus persistence in mice[J].J Immunol,1994,152(10):4976-4983. [63]OXENIUS A,ZINKERNAGEL RM,HENGARTNER H.Comparison of activation versus induction of unresponsiveness of virusspecific CD4+and CD8+T cells upon acute versus persistent viral infection[J].Immunity,1998,9(4):449-457. [64]ZHANG E,KOSINSKA A,LU M,et al.Current status of immunomodulatory therapy in chronic hepatitis B,fifty years after discovery of the virus:search for the"magic bullet"to kill ccc DNA[J].Antiviral Res,2015,123(11):193-203. [65]VANDEPAPELIERE P,LAU GK,LEROUX-ROELS G,et al.Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy:a randomized,control ed study of co-administration of HBs Ag/AS02 candidate vaccine and lamivudine[J].Vaccine,2007,25(51):8585-8597. [66]GAGGAR A,COESHOTT C,APELIAN D,et al.Safety,tolerability and immunogenicity of GS-4774,a hepatitis B virus-specific therapeutic vaccine,in healthy subjects:a randomized study[J].Vaccine,2014,32(39):4925-4931. [67]LOK AS,PAN CQ,HAN SH,et al.Safety and efficacy of GS-4774 in patients with chronic hepatitis B on oral antiviral therapy[J].Hepatology,2015,62:1181a. [68]FONTAINE H,KAHI S,CHAZALLON C,et al.Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B:a randomised trial——ANRS HB02 VAC-ADN[J].Gut,2015,64(1):139-147. -
本文二维码
计量
- 文章访问数: 2896
- HTML全文浏览量: 15
- PDF下载量: 616
- 被引次数: 0
下载:
